# Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

> **NCT02687906** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)** · enrollment: 39 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Vabomere

## Key facts

- **NCT ID:** NCT02687906
- **Lead sponsor:** Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02687906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02687906, "Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02687906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*